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Abstract
Different types of treatment, including surgery, medical therapy and radiotherapy, are possible in achieving control of
acromegaly. Of the medical therapies available, somatostatin analogues are effective in the majority of patients and can
induce pituitary tumour shrinkage. The rationale and outcome of somatostatin analogue treatment before surgery in pa-
tients with acromegaly is briefly presented. In summary, the benefits of somatostatin analogues given preoperatively sho-
uld be considered carefully as optimisation of cardiovascular, respiratory and metabolic functions is clinically relevant for
perioperative morbidity. Somatostatin analogues also induce significant shrinkage of GH-secreting pituitary tumours, al-
though this does not seem to be helpful in terms of improved surgical outcome.
(Pol J Endocrinol 2007; 58 (4): 356–360)
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Streszczenie
W leczeniu akromegalii możliwe jest zastosowanie różnych form terapii (leczenie operacyjne, farmakoterapia, radiotera-
pia). Analogi somatostatyny wykazują skuteczność u większości pacjentów i mogą powodować zmniejszenie wielkości
gruczolaka przysadki. Krótki przegląd przedstawia uzasadnienie i wyniki stosowania analogów somatostatyny przed le-
czeniem chirurgicznym. W podsumowaniu, korzyści przedoperacyjnego zastosowania analogów somatostatyny powinny
być starannie rozważone celem optymalizacji zaburzeń kardiologicznych, oddechowych i metabolicznych ważnych dla
chorobowości okołooperacyjnej. Analogi somatostatyny powodują również istotne zmniejszenie guzów przysadki wy-
dzielających GH, chociaż nie udowodniono jego wpływu na poprawę wyników leczenia neurochirurgicznego.
(Endokrynol Pol 2007; 58 (4): 356–360)
Słowa kluczowe: akromegalia, analogi somatostatyny, zmniejszenie guza, leczenie operacyjne guzów przysadki
Introduction
Acromegaly is a rare disease associated with premature
mortality, mainly because of cardiovascular disease[1].
The control of levels of growth hormone (GH) to below
2.5 µg/L) and of IGF-I (normalised for age and gender)
is reported to bring mortality within the norm [2]. Sur-
gery, medical therapy and radiotherapy can all be used
to achieve disease control. First-line surgery is general-
ly effective in patients with small tumours [3]. In more
recent years first-line therapy with somatostatin analo-
gues has been shown to be efficacious in approximate-
ly 50% of patients and to induce tumour shrinkage by
> 30% on average in approximately 80% of patients
[4]. First-line medical treatment with dopamine agonist
is not efficacious but can be of help in combination with
somatostatin analogues [3]. Treatment with the recen-
tly available GH-receptor antagonist [5] is effective in
normalising IGF-I levels in 75–90% of patients resistant
to previous therapies [6] but cannot currently be used
as first-line treatment in Europe.
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Cardio- and cerebrovascular disease and respirato-
ry and metabolic dysfunction, the major complications
of acromegaly [2] are well known to be major risk fac-
tors before surgery, especially in the elderly [8]. There-
fore the control of hypertension, diabetes, arrhythmias,
diastolic dysfunction, pulmonary dysfunction and sle-
ep apnoea is important in patients undergoing ana-
esthesia and surgery.
This brief review reports on the rationale and out-
come of somatostatin analogue treatment before sur-
gery in patients with acromegaly.
Treatment with somatostatin analogues before
surgery and surgical outcome
Surgery is efficacious in controlling GH and IGF-I excess
in 70–90% of patients with microadenomas and appro-
ximately 50% of those with macroadenomas when the
surgery is performed by dedicated neurosurgeons with
experience in pituitary adenomas [9]. In a recent study
in which 506 patients were operated on for GH-secre-
ting adenomas [10], cure of acromegaly was obtained in
75.3% of 142 microadenomas, 74.2% of 105 intrasellar
macroadenomas and in less than 50% up to 10% of pa-
tients bearing larger tumours. This cure rate appears to
be similar to that observed with somatostatin analogues,
even if the numbers related to the latter treatment were
smaller [4]. Several studies have reported the efficacy of
treatment with somatostatin analogues before surgery
(Table I). The majority of the patients achieved disease
control with somatostatin analogues before surgery, and
tumour shrinkage (by more than 20%) was reported in
a variable percentage of patients. It is worth noting that
most of the studies were performed using a subcutane-
ous formulation of octreotide, which is less effective than
the depot formulations such as octreotide LAR (long-ac-
ting release) or lanreotide-autogel (slow release). The sta-
tistical estimation of disease control rose from a 68% suc-
cess rate for patients with macroadenomas treated with
Table I
Presurgical somatostatin treatment
Tabela I
Przedoperacyjne leczenie somatostatyną
Author (ref. no) Year Number Treatment Outcome
of patients
Type Dose Duration Remission Patients Degree of
(months) Rate (%) with Shrinkage
shrinkage  (%)
(%)
Barkan [28] 1988 10 OCT 0.15–1 mg/d 0.75–7.5 80 100 20–54
Plöckinger [29] 1994 10 OCT 0.3–1.5 mg/d 3–6 80 50 26–85
Lucas-Morante [30] 1994 10 OCT 0.3 mg/d 1.4 60 60 9–78
Stevenaert [31] 1996 64 OCT 0.3–1.5 mg/d 0.75–39 71 23 >25
Colao [15] 1997 21 OCT 0.15–0.6 mg/d 3–6 55 23 ≥ 30
Newman [32] 1998 26 OCT 0.3–1.75 mg/d 3–60 40 46 ≥ 10
Tamura [33] 1998 9 OCT 0.12–0.24 mg/d 0.5–1 89 67 ≥ 20
 infusion
Tachibana [34] 1999 3 OCT 0.2 mg/d 0.5 67 67 ~50
Kristof [35] 1999 11 OCT 0.15–0.9 mg/d 1.7–6.7 55 36 29–48
Baldelli [36] 2000 23 LAN 30 mg/q10–14d 6–24 78 22 ≥ 20
Colao [37] 2001 15 LAR 20–40 mg/q28d 15–24 73 80 25–100
Abe [38] 2001 90 OCT 0.1–1.5 mg/d 3–21 69 31 11–35
Amato [39] 2002 11 LAR 10–30 mg/q28d 24 37.5 36 10–25
Amato [39] 2002 12 LAN 30 mg/q10–14d 24 41 50 10–25
Bevan [40] 2002 27 OCT Æ LAR 0.3–0.6 mg/d Æ 12 79 73 > 30
Æ 20–30 mg/q28d
Colao [41] 2006 34 LAR 20–30 mg/q28d 6 69.7 74 > 30
Colao [4] 2006 99 LAN or LAR 20–30 mg/q28d 12 42.4 72.7 > 25
30–120 mg/q28d
OCT — s.c. octreotide, LAN — lanreotide, LAR — octreotide-LAR
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primary pharmacotherapy to 81% (and even 87% for
non-invasive macroadenomas) for patients undergoing
surgery followed by postoperative somatostatin analo-
gues [5]. The question of whether shrinkage of tumours
before surgery may facilitate their complete resection has
not been examined in a controlled randomised blinded
manner and therefore cannot be answered rigorously.
However, when the modern depot formulations are used
more than 80% of patients treated for 12 months have
a tumour shrinkage greater than 20% and more than 50%
have a tumour shrinkage greater than 50% [4]. These
results should be considered of major relevance in pa-
tients with large macroadenomas, where it is known that
there is little likelihood of cure with first-line surgery.
Peri-operative morbidity in patients treated with
somatostatin analogues before surgery
In the hands of experienced neurosurgeons morbidity
and mortality during and immediately after trans-sphe-
noidal excision of a GH-secreting tumour is low [11, 12].
In any case, the extent and magnitude of perioperative
complications should be assessed since most patients
can present with several severe systemic complications
[2]. The life expectancy of patients with acromegaly is
currently longer than in previous decades because of
improved medical care. It is, however, well known that
the longer the duration of the disease, the more likely
the occurrence of complications such as diabetes, car-
dio- and cerebrovascular disease and respiratory pro-
blems [2]. Thus the role of first-line pharmacotherapy
before surgery in preventing or ameliorating periope-
rative complications is an important clinical question.
Overall, patients with acromegaly experience ana-
esthetic morbidity [13]. In 28 patients with acromegaly
examined retrospectively and compared with 28 sex-
and age-matched controls undergoing general ana-
esthesia, 42.8% of the patients had anaesthetic-associa-
ted haemodynamic changes, compared with 17.8% in
the control group; during anaesthesia blood glucose
levels were higher and urine output was lower in the
patients compared with controls [13]. Importantly, a si-
gnificantly higher number of patients had a difficult
intubation (42.8% vs. 3.6%), and fiberoptic intubation was
required in 25% of patients with acromegaly compared
with none of the controls [13]. It is, therefore, likely that
reducing soft tissue swelling before surgery can reduce
the rate of complications during anaesthesia.
In addition to these direct effects on the anaesthetic
procedure, cardiovascular disease, the most important
determinant of morbidity and mortality in acromegaly,
is of concern for preoperative assessment. Before sur-
gery both overt and underlying cardiovascular disease
should be evaluated [2]. The most common manifesta-
tions include left ventricular hypertrophy with incre-
ased wall thickness and cavity dimension, ultimately
developing concentric biventricular cardiomyopathy
with diastolic and eventually systolic dysfunction, re-
duced left ventricular ejection fraction on effort and at
rest and finally cardiac failure [2]. Other complications,
including dyslipidaemia, insulin resistance or overt dia-
betes mellitus, may also contribute to ischaemic heart
disease, further compromise cardiovascular function [2],
and lead to deleterious effects during and after surgery.
Improved cardiac function has been reported with
octreotide, octreotide LAR, and lanreotide [2]. Surpri-
singly, even 1 d of octreotide infusion improved systo-
lic and diastolic functional indices at rest, anaerobic thre-
shold and workload and oxygen consumption at maxi-
mal exercise, as assessed by echocardiography and bi-
cycle ergometry [14]. An increased prevalence of simple
to life-threatening arrhythmias may complicate perio-
perative outcomes. The frequency of late potentials,
a predictor of ventricular dysrhythmias (including se-
vere ventricular dysrhythmias with sudden death), is
significantly higher in patients with active acromegaly
compared with healthy control subjects [2]. Three to six
months of either octreotide [15] or lanreotide [16] treat-
ment normalised electrocardiogram recordings in most
patients, and sinus arrhythmia, supra-ventricular and
ventricular tachycardia improved.
Hypertension occurs in 20–51% of patients with ac-
tive acromegaly [17] and aggravates acromegalic car-
diomyopathy, atherosclerosis, and cardio- and cerebro-
vascular disease [2]. Blood pressure control may not
correlate with GH or IGF-I levels and the effects of so-
matostatin analogues on blood pressure in patients with
acromegaly are unclear.
The integrity of the respiratory system is a critical
preoperative clinical concern because a twofold incre-
ase in mortality due to respiratory disorders has been
reported in acromegaly [2]. Respiratory disorders com-
monly occur in acromegaly and are mainly attributed
to changes in the thoracic cage, tissue swelling and thic-
kening of the upper respiratory tract and enlargement
and distortion of the glottic structures with additional
folds. Lowering GH levels using somatostatin analogu-
es before surgery may facilitate anaesthetic intubation,
as reported for improved sleep apneoa [18], and a de-
crease in tongue volume [19].
Preoperative control of blood sugar levels may be
efficiently achieved by standard therapy. However, GH
is a potent insulin antagonist, and carbohydrate intole-
rance and diabetes mellitus are encountered in up to
30% of patients with acromegaly (2). Elevated glucose
and insulin levels may complicate the peri-operative
period and a reduction in GH and IGF-I levels is expec-
ted to improve carbohydrate intolerance. However, the
effects of somatostatin analogues on carbohydrate to-
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lerance are variable, as either improvement or impair-
ment may be observed during treatment [20]. Altho-
ugh the final long-term effect of somatostatin analogu-
es on glucose tolerance is still poorly understood, the
possibility of controlling diabetes before surgery is ap-
pealing, as diabetic patients are known to be at higher
risk of developing adverse surgical outcomes related to
complications of the disease (atherosclerosis, nephropa-
thy, and neuropathy), poor wound healing and incre-
ased susceptibility to infection [21]. A recently available
treatment for acromegaly is the GH-receptor antagonist,
pegvisomant. This has been shown to improve glucose
tolerance in patients with acromegaly [7, 22, 23]. The use
of pegvisomant before surgery in diabetic patients with
acromegaly has never been reported, although it is li-
kely to improve glucose and insulin levels.
In summary, the benefits of somatostatin analogues
given preoperatively should be considered carefully, as
optimisation of the cardiovascular, respiratory and
metabolic functions is clinically relevant for periopera-
tive morbidity [24]. Indeed, first-line surgery should be
limited to patients with small enclosed tumours and
those who do not present systemic complications [24].
Somatostatin analogues also induce significant shrin-
kage of GH-secreting pituitary tumours, although this
does not seem to be helpful in terms of improved surgi-
cal outcome [25–27].
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